Yifan Pharmaceutical Co., Ltd. (002019.SZ) Latest Company News

Oct 23, 2026, 10:34 UTC
Yifan Pharmaceutical reported first-three-quarter 2026 revenue of 3.722 billion yuan, down 5.13% year over year, and attributable net profit of 297 million yuan, down 23.42%.
Source:
- finance.sina.cn
Oct 23, 2026, 10:34 UTC
Yifan Pharmaceutical reported third-quarter 2026 revenue of 1.254 billion yuan, down 2.61% year over year, and attributable net profit of 91.9534 million yuan, up 9.29%.
Source:
- finance.sina.cn
Oct 11, 2026, 08:09 UTC
Yifan Pharmaceutical said its wholly owned subsidiary, Hefei Yifan Biopharmaceutical, received an acceptance notice for its domestic marketing-authorization application for ixazomib citrate capsules.
Source:
- finance.sina.cn
Sep 30, 2026, 06:43 UTC
The U.S. FDA approved Yifan Pharmaceutical's subsidiary Evive Biotech to add a manufacturing site in China for Ryzneuta (efbemalenograstim alfa injection, sold in China as Yilishu).
Source:
- finance.sina.cn
Sep 28, 2026, 01:00 UTC
Yifan Pharmaceutical's subsidiary Evive Biotech completed first participant enrollment and dosing in a Phase II clinical trial of its self-developed drug F-652 combined with systemic corticosteroids for acute graft-versus-host disease after hematopoietic stem cell transplantation.
Source:
- finance.sina.cn
Sep 22, 2026, 01:10 UTC
On September 21, Yifan Pharmaceutical and South Korea's Boryung Pharmaceutical announced a partnership under which Yifan Pharmaceutical obtained exclusive general agency rights for Taxotere (docetaxel injection) in China, handling promotion, distribution and commercialization there.
Source:
- finance.sina.cn
- koreaherald.com
Aug 20, 2026, 04:13 UTC
Yifan Pharmaceutical established a new medical technology company, Hefei Huansheng Medical Technology Co., Ltd., in Hefei, China, with Zhang Xin as legal representative, indirectly wholly owned by Yifan Pharmaceutical.
Source:
- finance.sina.cn
Jul 21, 2026, 10:50 UTC
Yifan Pharmaceutical provided a maximum 2 billion yuan joint liability guarantee to its wholly-owned subsidiary Hefei Yifan by signing an agreement with China Merchants Bank Hefei Branch on July 21, 2026.
Source:
- finance.sina.cn
Jul 16, 2026, 10:46 UTC
Yifan Pharmaceutical repurchased 5,000,000 of its own shares via centralized competitive bidding on July 16, 2026, with a total consideration of 53.9436 million yuan.
Source:
- finance.sina.cn
- finance.sina.cn
Jul 13, 2026, 03:39 UTC
Yifan Pharmaceutical's subsidiary Hangzhou Xinfu obtained a food production license for its HMOs product 2'-FL from the Hangzhou Market Supervision Administration.
Source:
- finance.sina.cn

002019.SZ

Yifan Pharmaceutical reported first-three-quarter 2026 revenue of 3.722 billion yuan, down 5.13% year over year, and attributable net profit of 297 million yuan, down 23.42%.

Yifan Pharmaceutical reported third-quarter 2026 revenue of 1.254 billion yuan, down 2.61% year over year, and attributable net profit of 91.9534 million yuan, up 9.29%.

Yifan Pharmaceutical said its wholly owned subsidiary, Hefei Yifan Biopharmaceutical, received an acceptance notice for its domestic marketing-authorization application for ixazomib citrate capsules.

The U.S. FDA approved Yifan Pharmaceutical's subsidiary Evive Biotech to add a manufacturing site in China for Ryzneuta (efbemalenograstim alfa injection, sold in China as Yilishu).

Yifan Pharmaceutical's subsidiary Evive Biotech completed first participant enrollment and dosing in a Phase II clinical trial of its self-developed drug F-652 combined with systemic corticosteroids for acute graft-versus-host disease after hematopoietic stem cell transplantation.

On September 21, Yifan Pharmaceutical and South Korea's Boryung Pharmaceutical announced a partnership under which Yifan Pharmaceutical obtained exclusive general agency rights for Taxotere (docetaxel injection) in China, handling promotion, distribution and commercialization there.

Yifan Pharmaceutical established a new medical technology company, Hefei Huansheng Medical Technology Co., Ltd., in Hefei, China, with Zhang Xin as legal representative, indirectly wholly owned by Yifan Pharmaceutical.

Yifan Pharmaceutical provided a maximum 2 billion yuan joint liability guarantee to its wholly-owned subsidiary Hefei Yifan by signing an agreement with China Merchants Bank Hefei Branch on July 21, 2026.

Yifan Pharmaceutical repurchased 5,000,000 of its own shares via centralized competitive bidding on July 16, 2026, with a total consideration of 53.9436 million yuan.

Yifan Pharmaceutical's subsidiary Hangzhou Xinfu obtained a food production license for its HMOs product 2'-FL from the Hangzhou Market Supervision Administration.